2023-02-03T11:54:18-05:00 2022-06-30 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2021-07-01 135644916 THE LEUKEMIA & LYMPHOMA SOCIETYINC LEUK 9149495213 3 INTERNATIONAL DRIVE SUITE 200 RYE BROOK NY 10573 GORDON MILLER JR EVP CHIEF FIN OFFICE 9148218908 2023-02-01 true GORDON MILLER XXX-XX-XXXX DEVIN L DUNCAN P01249521 2127589700 2023-02-03 2021 2023-03-07 01:45:13Z LOUIS J DEGENNARO 3 INTERNATIONAL DRIVE SUITE 200 RYE BROOK NY 10573 675392108 false X WWW.LLS.ORG X 1949 NY OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. 19 19 1177 3000000 0 441317494 400540019 12281240 11597762 12298324 6919696 11766658 7939727 477663716 426997204 152554274 299213836 0 113748897 112055516 9126288 5554287 50603358 84418720 101798755 359848179 518622394 117815537 -91625190 743613782 693676206 229841284 321732744 513772498 371943462 X OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. false false 83342500 48847932 11597762 A) RESEARCH PROGRAMS: AT LLS, WE ARE PUSHING BOUNDARIES TOWARD POWERFUL NEW THERAPIES. WE PROPEL GROUNDBREAKING CANCER TREATMENTS THROUGH ALL PHASES OF THE DRUG APPROVAL PROCESS AND ARE PROUD THAT OUR SUPPORT HAS BEEN KEY TO ADVANCING 75% OF THE ALMOST 100 BLOOD CANCER TREATMENT APPROVALS OVER THE LAST FIVE YEARS. AS WE CONTINUED TO SUPPORT THE SEARCH FOR LIFESAVING AND LESS TOXIC TREATMENTS IN 2022, WE INVESTED IN EXCITING RESEARCH FRONTIERS, INCLUDING PRECISION MEDICINE, IMMUNOTHERAPY, AND LINKS BETWEEN MUTATIONS AND BLOOD CANCER-ADVANCEMENTS THAT ARE CHANGING THE PARADIGM OF CANCER TREATMENT. IN THE PROCESS, WE PROPELLED SEVERAL NOVEL SCIENCE INITIATIVES TO NEW HEIGHTS-MANY OF WHICH HARDLY SEEMED POSSIBLE JUST A SHORT TIME AGO. WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. TO DATE, LLS HAS INVESTED OVER 1.6 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. OUR SUSTAINED RESEARCH INVESTMENT OVER MULTIPLE DECADES HAS PAID OFF HANDSOMELY. THIS IS BEST DEMONSTRATED BY OUR SEMINAL INVESTMENT IN CHIMERIC ANTIGEN RECEPTOR T CELL (CAR T) THERAPY STARTING IN 1990 THAT, SINCE 2017, HAS TRANSLATED INTO A 12 FDA-APPROVED CAR T THERAPIES FOR ACUTE B-CELL LEUKEMIA, NON-HODGKIN LYMPHOMA, AND MULTIPLE MYELOMA. CAR T THERAPY HAS IN SOME CASES PRODUCED CURES IN PATIENTS WHO HAVE FAILED ALL OTHER THERAPEUTIC OPTIONS. IN FISCAL YEAR 2022, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 9 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 54.6 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. IMPACT RESEARCH GRANTS TO ADDRESS UNEQUAL REPRESENTATION OF UNDERSERVED POPULATIONS IN CLINICAL TRIALS, IN MAY WE INTRODUCED IMPACT (INFLUENTIAL MEDICINE PROVIDING ACCESS TO CLINICAL TRIALS) RESEARCH GRANTS. AN INITIAL FIVE-YEAR INVESTMENT OF 3.75 MILLION WAS ALLOCATED TO MAYO CLINIC, VANDERBILT UNIVERSITY MEDICAL CENTER, AND WEILL CORNELL MEDICINE IN NEW YORK CITY. WE NOW HAVE SIX IMPACT RESEARCH GRANTS IN PLACE SINCE OCTOBER 2022. THE IMPACT GRANTS WILL HELP THESE MAJOR CANCER CENTERS EXPAND CLINICAL TRIAL ACCESS TO LOCAL COMMUNITY-BASED HOSPITALS AND CLINICS WITH SUBSTANTIAL UNDERSERVED POPULATIONS. THE GOAL IS TO INCREASE TRIAL ENROLLMENT AMONG TRADITIONALLY UNDERSERVED POPULATIONS, INCLUDING RACIAL AND ETHNIC MINORITIES, RURAL RESIDENTS, AND INDIVIDUALS WITH LOW INCOME, TO AT LEAST 20%, THEREBY EXPANDING ACCESS TO STATE-OF-THE-ART THERAPIES TO A BROADER SWATH OF NEWLY DIAGNOSED BLOOD CANCER PATIENTS. THERAPY ACCELERATION PROGRAM (TAP) SINCE 2007, OUR INNOVATIVE VENTURE PHILANTHROPY INITIATIVE, THE LLS THERAPY ACCELERATION PROGRAM (TAP), HAS PARTNERED WITH OVER 70 BIOTECHNOLOGY COMPANIES AND ACADEMIC RESEARCHERS TO EXTEND THE THERAPEUTIC LANDSCAPE IN LEUKEMIA, LYMPHOMA, AND MULTIPLE MYELOMA BY INVESTING OVER 130 MILLION DOLLARS, AND SO FAR, LEADING TO 3 FDA APPROVALS. CURRENTLY, THERE ARE OVER 20 ACTIVE CLINICAL STUDIES WITH TAP-SUPPORTED THERAPIES, INCLUDING 4 LATE- STAGE CLINICAL STUDIES WITH CLINICAL DATA EXPECTED IN THE NEXT YEAR OR TWO THAT COULD LEAD TO NEW FDA APPROVALS FOR BLOOD CANCER PATIENTS. IN 2022, WE MADE FOUR INVESTMENTS IN COMPANIES DEVELOPING NEXT-GENERATION IMMUNOTHERAPIES INCLUDING TWO FROM EUROPE. THESE INVESTMENTS GO BEYOND THE TRADITIONAL T CELL THERAPY SUCH AS CAR-T OR BI-SPECIFICS AND INCLUDE TWO CHECKPOINT INHIBITORS USING MACROPHAGES OR MYELOID CELLS TO ELICIT THE ANTI-CANCER EFFECTS. WE ALSO INVESTED IN COMPANIES DEVELOPING NOVEL ANTIBODIES, ONE A GAMMA-DELTA T CELL ACTIVATING ANTIBODY FOR A VARIETY OF BLOOD CANCERS AND ANOTHER ANTIBODY FOR A NOVEL TARGET IN PATIENTS WITH RARE BLOOD CANCERS INCLUDING LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AND CYTOTOXIC LYMPHOMAS WHERE THERE IS NO STANDARD OF CARE AND CURRENT THERAPIES ARE TOO TOXIC FOR PATIENTS. ALL FOUR COMPANIES ARE IN ACTIVE CLINICAL DEVELOPMENT IN BLOOD CANCERS. NATIONAL PATIENT REGISTRY COVID INFORMATION THE ONGOING COVID-19 PANDEMIC ENGENDERED A HOST OF FEARS AND QUESTIONS FOR THE BLOOD CANCER COMMUNITY. WHEN PATIENT CONCERNS AROSE ABOUT WHETHER THE NEW VACCINES WOULD PROTECT THEM, LLS STEPPED IN TO FIND ANSWERS. IN FEBRUARY 2021, LLS ACTIVATED THE LLS NATIONAL PATIENT REGISTRY, A PROJECT SUPPORTED BY ETHEL AND BERNARD GARIL IN MEMORY OF THEIR SON, MICHAEL, WHO SUCCUMBED TO ACUTE LYMPHOBLASTIC LEUKEMIA. MORE THAN 10,000 BLOOD CANCER PATIENTS ANSWERED THE CALL TO JOIN THE REGISTRY AS "CITIZEN SCIENTISTS." THIS ALLOWED US TO GENERATE THE LARGEST DATA SET REPORTED TO DATE ON VACCINE SAFETY AND EFFICACY(INCLUDING BOOSTERS) ACROSS ALL MAJOR BLOOD CANCER AND TREATMENT TYPES. THIS INFORMATION HAS HELPED PATIENTS, HEALTHCARE PROVIDERS, AND PUBLIC HEALTH OFFICIALS MAKE MORE INFORMED CHOICES ABOUT COVID-19 PREVENTION. CLINICAL TRIALS BEAT AML MASTER TRIAL BEGINNING NOVEMBER 2016, LLS LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. PEDAL MASTER TRIAL IN 2022, LLS LAUNCHED LLS' PEDIATRIC ACUTE LEUKEMIA (PEDAL) MASTER CLINICAL TRIAL. THIS UNPRECEDENTED INTERNATIONAL COLLOBORATION BETWEEN LLS, THE NATIONAL CANCER INSTITUTE (NCI), THE CHILDREN'S ONCOLOGY GROUP (OCG) AND OTHER PARTNERS BREAKS NEW GROUND, BRINGING PRECISION MEDICINE TO THE TREATMENT OF PEDIATRIC RELAPSED ACUTE LEUKEMIA. RATHER THAN A "ONE SIZE FITS ALL" APPROACH, PEDAL USES GENOMICS AND OTHER BIOMARKERS TO CUSTOMIZE TREATMENT, ALLOWING INNOVATIVE THERAPIES TO BE MATCHED TO PATIENTS BASED ON THEIR UNIQUE TUMOR BIOLOGY. A WIDE RANGE OF TRIAL SCREENIN LOCATIONS - SPANNING EUROPE, AUSTRALIA, NEW ZEALAND, CANADA, AND OVER 200 US SITES - ENSURES WIDESPREAD PARTICIPATION. ARKANSAS CHILDRESN'S HOSPITAL BECAME THE FIRST US THERAPEUTIC TRIAL SITE IN 2022, WITH MORE TO COME. 296248725 250365904 B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1.5 MILLION PEOPLE ACROSS THE UNITED STATES (US) ARE CURRENTLY LIVING WITH OR ARE IN REMISSION FROM LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OF PATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. FINANCIAL ASSISTANCE OUR FINANCIAL ASSISTANCE PROGRAMS AIM TO LESSEN THE ECONOMIC TOLL ON PATIENTS AND FAMILIES TO HELP PATIENTS AFFORD LIFE-SAVING TREATMENTS. TO COUNTER CONTINUALLY RISING DRUG PRICES AND ALLEVIATE THE BURDENS FELT BY PATIENTS COPING WITH BLOOD CANCER, WE PROVIDED MORE THAN 75,400 PATIENTS WITH OVER 384M IN ASSISTANCE AWARDED, A 59% INCREASE OVER LAST YEAR. THE LION'S SHARE-OVER 371 MILLION- AWARDED TO SUPPORTED PATIENTS' INSURANCE PREMIUMS AND TREATMENT-RELATED CO-PAY AND CO-INSURANCE OUT OF POCKET COSTS THROUGH OUR CO-PAY ASSISTANCE PROGRAM. IN KEEPING WITH OUR COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION, LLS RECOGNIZES THAT NEED EXISTS THROUGHOUT ALL GEOGRAPHIC REGIONS AND WITHIN ALL PATIENT POPULATIONS, INCLUDING THOSE TRADITIONALLY UNDERREPRESENTED. IN FY22, FINANCIAL ASSISTANCE WAS PROVIDED TO PATIENTS WHO RESIDED IN 82% OF ALL U.S. COUNTIES AND 74% OF THE COUNTIES ACROSS THE U.S. WITH THE HIGHEST POVERTY RATES. CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2022, CO-PAY ASSISTANCE WAS PROVIDED TO OVER 36,800 PATIENTS. SUSAN LANG PRE CAR T-CELL THERAPY TRAVEL ASSISTANCE PROGRAM LLS PROVIDED OVER 420 GRANTS, EACH 2,500, FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS FOR PATIENTS WHO ARE BEING EVALUATED TO RECEIVE CAR T-CELL THERAPY AS EITHER STANDARD TREATMENT OR A CLINICAL TRIAL. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM LLS AWARDED A 500 GRANT TO OVER 11,050 PATIENTS FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS. URGENT NEED PROGRAM IN PARTNERSHIP WITH MOPPIE'S LOVE AND CHARLIE'S FUND, LLS PROVIDED A 500 GRANT TO NEARLY 11,750 PATIENTS AND FAMILIES IN ACUTE FINANCIAL NEED FOR NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES, AND FOOD. PATIENT AID PROGRAM LLS AWARDED ONE-TIME STIPENDS OF 100 TO OVER 15,400 PATIENTS TO HELP OFFSET NON-MEDICAL EXPENSES. SCHOLARSHIP FOR BLOOD CANCER SURVIVORS IN 2022, THE LLS SCHOLARSHIP FOR BLOOD CANCER SURVIVORS PROVIDED UP TO 7,500 IN TUITION SUPPORT TO 100 PATIENTS, FOR VIRTUAL OR IN-PERSON VOCATIONAL, TWO-YEAR, OR FOUR-YEAR UNDERGRADUATE EDUCATION. 19723379 C) PUBLIC HEALTH EDUCATION: LLS BELIEVES KNOWLEDGE IS POWER. AS ALWAYS, LLS HAS OFFERED THEIR INFORMATIONAL PROGRAMS IN VIRTUAL FORMATS, CONTINUING TO PROVIDE VITALLY NEEDED EDUCATION AND EMOTIONAL SUPPORT FOR THOSE IMPACTED BY BLOOD CANCER. ONGOING PANDEMIC CONCERNS TRAINED ONCOLOGY INFORMATION SPECIALISTS IN OUR INFORMATION RESOURCE CENTER (IRC) WERE AVAILABLE TO ANSWER PANDEMIC-RELATED AND OTHER QUESTIONS. NEARLY 26,000 INTERACTIONS BETWEEN THE IRC AND PATIENTS AND CAREGIVERS TOOK PLACE, WITH AVERAGE CALL LENGTHS UP 14% OVER 2021. FACILITATING CLINICAL TRIAL ACCESS THE LLS CLINICAL TRIAL SUPPORT CENTER (CTSC) GREW THROUGHOUT THE YEAR AS WE INCREASED OUR BI-LINGUAL AND PEDIATRIC EXPERTISE AMONG THE CTSC NURSE NAVIGATORS, AND CONTINUED TO EXPAND THE POSSIBILITY OF POSITIVE OUTCOMES FOR PATIENTS BY MATCHING THEM TO SUITABLE CLINICAL TRIALS. OUR NURSE NAVIGATORS ASSISTED 1,005 PATIENTS (ABOUT THE SAME AS IN 2021). OF THE 751 NEW PATIENTS ASSISTED, 19% ENTERED A TRIAL. OUTREACH TO UNDERSERVED GROUPS WE AUGMENTED EFFORTS TO EXPAND ACCESS TO LLS SERVICES AND RESOURCES BY BOLSTERING RELATIONS WITH COMMUNITY GROUPS AND LEADERS, NOTABLY IN THE BLACK AND LATINO COMMUNITIES, AND INCREASED OUR NUMBER OF BILINGUAL VOLUNTEERS. WE ALSO INCREASED ACCESSIBILITY OF OUR EDUCATION PROGRAMS TO RURAL PATIENTS AND FAMILIES VIA OUR VIRTUAL OFFERINGS. MOREOVER, WE EXPANDED PARTNERSHIPS WITH AFFINITY GROUPS INCLUDING: THE NATIONAL COALITION OF 100 BLACK WOMEN, THE BLACK CAUCUS OF THE AMERICAN LIBRARY, VISIONS Y COMPROMISO AND THE MEXICAN CONSULATE'S VENTANILLA DE SALUD PROGRAM. THE LLS MYELOMA LINK PROGRAM, LAUNCHED IN 2017, CONTINUED TO GAIN TRACTION. WE IMPROVED UNDERSTANDING OF TREATMENT OPTIONS BY PROVIDING IMPORTANT INFORMATION TO AFRICAN AMERICANS, WHO ARE TWICE AS LIKELY TO BE DIAGNOSED WITH MULTIPLE MYELOMA AS CAUCASIAN AMERICANS. IN 2022, LLS REACHED NEARLY 22,000 PEOPLE THROUGH MORE THAN 60 MYELOMA LINK EDUCATION AND OUTREACH ACTIVITIES IN 13 CITIES. EDUCATION AND PATIENT CONNECTIONS OUR VIRTUAL EDUCATION PROGRAMS PROVIDED BOTH PATIENTS AND FAMILIES, AS WELL AS HEALTH CARE PROFESSIONALS, ACCESS TO CONTENT INCLUDING BLOOD CANCER CONFERENCES, LOCAL EDUCATION PROGRAMS, NATIONAL WEBINARS, VIDEOS, LECTURES, AND PODCASTS. LLS'S HIGHLY VIEWED WEBSITE CONTINUES TO PROVIDE THE MOST UP TO DATE BLOOD CANCER INFORMATION INCLUDING ACCESS TO BLOGS, BOOKLETS, WORKBOOKS, FACT SHEETS AND MORE. IN ADDITION, 1,060 CANCER PATIENTS WERE PROVIDED WITH PERSONALIZED NUTRITION CONSULTATIONS BY LLS'S REGISTERED DIETITIAN. OUR PATIENT & COMMUNITY OUTREACH TEAM CONTINUED TO BRING PATIENTS TOGETHER VIA ONLINE LOCAL SUPPORT GROUPS AND CHATS. THE PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM MATCHED NEARLY 2,100 PATIENTS (UP 17% FROM 2021) WITH TRAINED VOLUNTEERS FACING THE SAME DISEASE, HELPING TO AVERT PANDEMIC-RELATED ISOLATION. IN ADDITION, MEMBERSHIP IN LLS COMMUNITY-OUR ONLINE SOCIAL NETWORK- WAS 19,181, AN INCREASED 8% OVER 2021. 11983999 D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2022: -LLS PROVIDED 14 CME/CE-GRANTING VIRTUAL EDUCATIONAL PROGRAMS, WITH 873 HEALTHCARE PROFESSIONALS IN ATTENDANCE. - OVER 28,000 PATIENTS AND PROFESSIONALS PARTICIPATED IN LIVE EDUCATION PROGRAMS DELIVERED VIRTUALLY AS WELL AS DELIVERED IN PERSON, LOCALLY AND REGIONALLY. --THERE WERE 104,173 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 35,663 VIRTUAL LECTURE VIEWS AND 97,685 PODCAST DOWNLOADS. 11983999 411298603 true true false true false false false true false true true false false false false true false true false true true true false true true false false true true true false false false false false false false false true false false false true true true false false false true 253 0 true 1177 true false true CA false false false true true false false false false false false X 19 19 false false true false false false false true true false true true true true true true true true true true false AK AL AR AZ CA CO CT DE DC FL GA HI ID IL IN KS KY LA MA MD ME MI MN MO MS NH NJ NM NE NY OH OK OR PA PR RI SC TN UT VA WA WI WV X X GORDON MILLER JR 9148218935 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 LOUIS J DEGENNARO PRESIDENT & 40.00 1.00 X 1011186 0 51204 GWEN NICHOLS MD EVP CHIEF ME 40.00 X 609795 0 43790 TROY DUNMIRE EVP CHIEF OP 40.00 X 593456 0 24936 GORDON MILLER JR EVP CHIEF FI 40.00 1.00 X 482778 0 55947 DALE NISSENBAUM EVP GEN COUN 40.00 X 493477 0 19326 COKER POWELL SVP CHIEF DE 40.00 X 439953 0 65803 TOM OSGOOD EVP CHIEF HR 40.00 X 437669 0 31401 VANESSA WHITE SVP CHIEF AD 40.00 X 424061 0 39696 LEE M GREENBERGER SVP CHIEF SC 40.00 X 384232 0 66083 RICHARD BAGGER BOD MEMBER 4.00 X 0 0 0 MICHELE CAMERON BOD MEMBER 4.00 X 0 0 0 RUBEN MESA MD FACP AT LARGE 4.00 X X 0 0 0 CHRISTOPHER FLOWERS BOD MEMBER 4.00 X 0 0 0 JOHN GREENE BOD MEMBER 4.00 X 0 0 0 FRANCIE HELLER BOD MEMBER 4.00 X 0 0 0 RALPH E LAWSON BOD MEMBER 4.00 X 0 0 0 CASEY CUNNINGHAM MD BOD MEMBER 4.00 X 0 0 0 JANICE GABRILOVE MD BOD MEMBER 4.00 X 0 0 0 RENZO CANETTA MD BOD MEMBER 4.00 X 0 0 0 KATHLEEN MERIWETHER VICE CHAIR 4.00 X X 0 0 0 LYNNE O'BRIEN BOD MEMBER 4.00 X 0 0 0 MARLA PERSKY BOD MEMBER 4.00 X 0 0 0 RICHARD RENDINA BOD MEMBER 4.00 X 0 0 0 ROBERT ROSEN BOD MEMBER 4.00 X 0 0 0 JEFF SACHS CHAIR 4.00 X X 0 0 0 BART SICHEL BOD MEMBER 4.00 X 0 0 0 ALESSANDRA TOCCO BOD MEMBER 4.00 X 0 0 0 FREDA WANG SECRETARY/TR 4.00 X X 0 0 0 4876607 398186 249 false true false SYNEOS HEALTH LLC 75 REMITTANCE DRIVE SUITE 3160 CHICAGO IL 606753160 CLINICAL TRIAL 12330415 PATIENT ADVOCATE FOUNDATION 421 BUTLER FARM RD HAMPTON VA 23666 PAT ASSIST PROC 10257027 RESOURCE ONE 2900 EAST APACHE STREET TULSA OK 74110 DIRECT MARKETIN 4883318 META PLATFORMS 1 HACKER WAY MENLO PARK CA 94025 ADVERTISING 3223672 SALESFORCE 140 E 45TH ST NEW YORK NY 10017 SOFTWARE 3164175 159 335805 158942124 241262090 1872690 400540019 SERVICE REVENUE 810000 11597762 11597762 11597762 8431107 8431107 9656656 9656656 231878526 233389937 -1511411 -1511411 -1511411 13288038 158942124 15004967 -1716929 -1716929 426997204 11597762 14859423 41209239 41209239 250365904 250365904 7638693 7638693 2091645 852283 964653 274709 88505319 44161169 24395966 19948184 2518213 1197908 744063 576242 12346404 5899281 3610032 2837091 6593935 3136721 1948327 1508887 4725702 2835421 1275940 614341 525457 525457 2481864 2481864 5554287 5554287 227786 185052 22949 19785 25326073 14532268 4545117 6248688 8707809 5462742 1158998 2086069 15269287 9381269 1794807 4093211 13589410 1024642 10094213 2470555 7379563 3813240 1630868 1935455 1716709 898977 398793 418939 3963430 2304535 1000913 657982 1375286 812084 351295 211907 RESEARCH AND DEVELOPMENT 9757258 9753950 2639 669 MISCELLANEOUS 6753121 3351361 2255403 1146357 518622394 411298603 56720433 50603358 X 14309133 9558392 4750741 17101591 10533722 118564418 59563249 13531687 24346058 3702570 5700688 22230984 11696883 10748048 10534101 552134623 560279919 20423995 20361812 7406850 2356657 743613782 693676206 28917585 29802071 188608360 278233023 12315339 13697650 229841284 321732744 X 328718773 301387942 185053725 70555520 513772498 371943462 743613782 693676206 -91625190 -50203846 X false true X true false X 419570497 372750094 427419530 441317494 400540019 2061597634 419570497 372750094 427419530 441317494 400540019 2061597634 559389444 1502208190 8235985 11830162 29082073 16877123 18087763 84113106 70000 70000 2145780740 83180015 0.70010 0.70390 X PART II, LINE 10 OTHER MISC. REVENUE (YR 2017) 70,000 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED true true true 219672 false true 130387 false true 489524 true 218281 true 1424000 2481864 false SCHEDULE C, PART II-B, LINE 1 LLS PARTICIPATES IN A NUMBER OF COALITIONS AND MEMBER ORGANIZATIONS, INCLUDING ALLIANCE FOR A STRONGER FDA, ALLIANCE FOR CHILDHOOD CANCER, CANCER LEADERSHIP COUNCIL, DEFENSE HEALTH RESEARCH CONSORTIUM, FRIENDS OF CANCER RESEARCH, NCSL FOUNDATION FOR STATE LEGISLATURES, ONE VOICE AGAINST CANCER, PARTNERSHIP TO PROTECT COVERAGE, PATIENT QUALITY OF LIFE COALITION, PUBLIC AFFAIRS COUNCIL, AND STATE ACCESS TO INNOVATIVE MEDICINES COALITION. EMPLOYEES IN THE LLS OFFICE OF PUBLIC POLICY WORK TO ADVANCE THE ORGANIZATIONS PUBLIC POLICY PRIORITIES, DOING SO WITH SUPPORT FROM LOBBYING FIRMS AND ADVISERS RETAINED BY LLS AND IN PARTNERSHIP WITH VOLUNTEER ADVOCATES. LLS VOLUNTEER ADVOCATES ENGAGE THEIR LAWMAKERS BY CONDUCTING LETTER-WRITING CAMPAIGNS, SHARING THEIR PERSONAL STORIES, AND CONDUCTING ONE-ON-ONE VISITS IN STATE CAPITOLS AND IN WASHINGTON, D.C. ALL WITH SUPPORT FROM THE LLS OFFICE OF PUBLIC POLICY. X false 7381460 1129903 -913685 -295324 -14061 7288293 5902791 1650 1726314 -236177 -13118 7381460 6168319 -8812 -246718 -9998 5902791 6192807 292934 -304999 -12423 6168319 5897377 200 546324 -237896 -13198 6192807 0.54600 0.45400 false false 1214662 866323 348339 20964776 10779014 10185762 51546 51546 10534101 X 443864558 1356633 3262633 12475875 17095141 426769417 227787 227787 426997204 534237404 3262633 12580164 15842797 518394607 227787 227787 518622394 SCHEDULE D, PAGE 2, PART III, LINE 4 THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS. SCHEDULE D, PAGE 2, PART V, LINE 4 LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS. SCHEDULE D, PAGE 3, PART X LLS, LLSRP, AND LLSRF QUALIFY AS CHARITABLE ORGANIZATIONS AS DEFINED BY INTERNAL REVENUE CODE SECTION 501(C)(3) AND, ACCORDINGLY, ARE EXEMPT FROM FEDERAL INCOME TAXES UNDER INTERNAL REVENUE CODE SECTION 501(A). ADDITIONALLY, SINCE THESE ORGANIZATIONS ARE PUBLICLY SUPPORTED, CONTRIBUTIONS QUALIFY FOR THE MAXIMUM CHARITABLE CONTRIBUTION DEDUCTION UNDER THE INTERNAL REVENUE CODE. LLSC IS REGISTERED AS A CHARITABLE ORGANIZATION UNDER THE INCOME TAX ACT (CANADA) AND IS, THEREFORE, NOT SUBJECT TO INCOME TAXES IF CERTAIN DISBURSEMENT REQUIREMENTS ARE MET. LLS AND ITS RELATED ENTITIES RECOGNIZE THE EFFECT OF TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. THERE WERE NOT ENTITIES THAT RECOGNIZED UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2022 AND JUNE 30, 2021. SCHEDULE D, PAGE 4, PART XI, LINE 2D LLS CANADA REVENUE 12,475,875 SCHEDULE D, PAGE 4, PART XII, LINE 2D LLS CANADA EXPENSES 12,580,164 true NORTH AMERICA 1 RESEARCH FUNDING RESEARCH GRANTS 618500 EUROPE RESEARCH FUNDING RESEARCH GRANTS 5143371 CENTRAL AMERICA & CARIBBEAN INVESTMENTS INVESTMENTS 8391601 MIDDLE EAST & NORTH AFRICA RESEARCH FUNDING RESEARCH GRANTS 120000 EAST ASIA & THE PACIFIC RESEARCH FUNDING RESEARCH GRANTS 1756822 EUROPE INVESTMENTS INVESTMENTS 464018 1 1 16494312 16494312 NORTH AMERICA RESEARCH GRANT 150000 WIRE PAYMENT ACCRUAL EUROPE RESEARCH GRANT 600000 WIRE PAYMENT ACCRUAL EUROPE RESEARCH GRANT 200000 WIRE PAYMENT ACCRUAL EUROPE RESEARCH GRANT 99962 WIRE PAYMENT ACCRUAL EUROPE RESEARCH GRANT 10000 WIRE PAYMENT ACCRUAL EAST ASIA AND PACIFIC RESEARCH GRANT 250000 WIRE PAYMENT ACCRUAL EAST ASIA AND PACIFIC RESEARCH GRANT 1031822 WIRE PAYMENT ACCRUAL EAST ASIA AND PACFIC RESEARCH GRANT 350000 WIRE PAYMENT ACCRUAL NORTH AMERICA RESEARCH GRANT 318500 WIRE PAYMENT ACCRUAL MIDDLE EAST AND NORTH AFRICA RESEARCH GRANT 120000 WIRE PAYMENT ACCRUAL EAST ASIA AND PACIFIC RESEARCH GRANT 125000 WIRE PAYMENT ACCRUAL NORTH AMERICA RESEARCH GRANT 150000 WIRE PAYMENT ACCRUAL EUROPE RESEARCH GRANT 250000 WIRE PAYMENT ACCRUAL EUROPE RESEARCH GRANT 125000 WIRE PAYMENT ACCRUAL EUROPE RESEARCH GRANT 250000 WIRE PAYMENT ACCRUAL EUROPE RESEARCH GRANT 399995 WIRE PAYMENT ACCRUAL EUROPE RESEARCH GRANT 249977 WIRE PAYMENT ACCRUAL EUROPE RESEARCH GRANT 125000 WIRE PAYMENT ACCRUAL EUROPE RESEARCH GRANT 193182 WIRE PAYMENT ACCRUAL EUROPE RESEARCH GRANT 63221 WIRE PAYMENT ACCRUAL EUROPE RESEARCH GRANT 114123 WIRE PAYMENT ACCRUAL EUROPE THERAPY ACCELERATION 1310105 WIRE PAYMENT FMV EUROPE THERAPY ACCELERATION 250000 WIRE PAYMENT FMV EUROPE RESEARCH GRANT 902806 WIRE FMV 24 true false true true false false SCHEDULE F, PAGE 1, PART I, LINE 2 FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. THE ACCOUNTING METHOD UTILIZED FOR GRANTS REPORTED ON PART II IS THE ACCRUAL METHOD AS CONSISTENT WITH BOOKS AND RECORDS. SCHEDULE F, PAGE 1, PART I, LINE 3 NORTH AMERICA 618,500 0 EUROPE 5,143,371 0 CENTRAL AMERICA & CARIBBEAN 0 8,391,601 MIDDLE EAST & NORTH AFRICA 120,000 0 EAST ASIA & THE PACIFIC 1,756,822 0 EUROPE 0 464,018 X X X X X X X true RESOURCE ONE 2900 EAST APACHE STREET TULSO OK 74110 DIRECT MAI false 4883318 -4883318 THOMPSON HABIB & DENISON 80 HAYDEN AVENUE SUITE 300 LEXINGTON MA 02421 DIRECT MAI false 670969 -670969 5554287 -5554287 All States STUDENT VISIONA 3702932 3531242 171690 9215 161718 889 362 LAKE TAHOE BIKE 3491630 3298234 193396 18104 48991 21164 260674 323 165035600 152112648 12922952 2032811 7616287 3103115 353146 1378491 172230162 158942124 13288038 2042026 7796109 3152995 374310 1639527 15004967 -1716929 SCHEDULE G, PART IV SCHEDULE G PART I, LINE 2B LLS USED RESOURCE ONE AND THOMPSON HABIB, & DENISON FOR IT'S NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. SCHEDULE G PART II - LINE 2 CONTRIBUTIONS REPRESENT THE CASH DONATIONS IN EXCESS OF FAIR MARKET VALUE BENEFITS PROVIDED TO THE DONOR. true ALBERT EINSTEIN COLLEGE OF MEDICINE RESEARCH FINANCE 1300 MORRIS PARK AVE BELFER 1108 BRONX NY 10461 472209056 3 157000 ACCRUAL RESEARCH GRANT ATRIUM HEALTH FOUNDATION 208 EAST BOULEVARD ATTN ELECTA MCPHERSON CHARLOTTE NC 28203 566060481 3 19565 ACCRUAL RESEARCH GRANT BAYLOR COLLEGE OF MEDICINE BAYLOR COLLEGE OF MEDICINE P O BOX 301207 DALLAS TX 753031207 741613878 3 1914672 ACCRUAL RESEARCH GRANT BE THE MATCH FOUNDATION 500 N 5TH STREET MINNEAPOLIS MN 55401 411704734 3 300000 ACCRUAL RESEARCH GRANT BECKMAN RESEARCH INSTITUTE OF THE C 1500 EAST DUARTE ROAD ATTN VALERIE BINGHAM DUARTE CA 91010 953432210 3 1705029 ACCRUAL RESEARCH GRANT BOARD OF TRUSTEES OF THE LELAND STA STANFORD UNIVERSITY LOCKBOX SAN FRANCISCO CA 941444253 941156365 3 1577466 ACCRUAL RESEARCH GRANT BRIGHAM AND WOMENS HOSPITAL RESEARCH PO BOX 3149 BOSTON MA 022413149 042312909 3 194008 ACCRUAL RESEARCH GRANT CINCINNATI CHILDREN'S HOSPITAL MEDI 3333 BURNET AVENUE ML 4900 CINCINATTI OH 45229 310833936 3 741675 ACCRUAL RESEARCH GRANT CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND OH 44195 340714585 3 410000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE RESEARCH ACCOUNTING MAIL STOP BP43 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 3 2864999 ACCRUAL RESEARCH GRANT EMORY UNIVERSITY EMORY UNIVERSITY PO BOX 935084 ATLANTA GA 311935084 582137993 3 1499219 ACCRUAL RESEARCH GRANT FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVENUE NORTH J6-300 SEATTLE WA 981091024 237156071 3 1972000 ACCRUAL RESEARCH GRANT H LEE MOFFITT CANCER CENTER & RESE PO BOX 742801 ATLANTA GA 303742801 593238634 3 61919 ACCRUAL RESEARCH GRANT HACKENSACK MERIDIAN HEALTH 40 PROSPECT AVENUE ATTN DAVID CANDELMO OFFICE OF RE HACKENSACK NJ 07601 010649794 3 99000 ACCRUAL RESEARCH GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT S ATTN RAJ APPAVU ONE GUSTAVE L LEVY PLACE BOX 350 NEW YORK NY 10029 136171197 3 612750 ACCRUAL RESEARCH GRANT INDIANA UNIVERSITY OFFICE OF RESEARCH ADMINISTRATION PO BOX 78000 DETROIT MI 482780867 356018940 3 18822 ACCRUAL RESEARCH GRANT INTERNATIONAL WALDENSTROM'S MACROGL 6144 CLARK CENTER AVE SARASOTA FL 34238 541784426 3 100000 ACCRUAL RESEARCH GRANT JOAN & SANFORD I WEILL MEDICAL COL 575 LEXINGTON AVE 9TH FL ATTN MELISSA PARAY NEW YORK NY 10022 131623978 3 1332500 ACCRUAL RESEARCH GRANT MASSACHUSETTS GENERAL HOSPITAL MGH RESEARCH FINANCE PO BOX 414876 BOSTON MA 022414876 041564655 3 1131249 ACCRUAL RESEARCH GRANT MAYO CLINIC ROCHESTER MAYO CLINIC RESEARCH PO BOX 860334 MINNEAPOLIS MN 554860334 416011702 3 275000 ACCRUAL RESEARCH GRANT MYELOPROLIFERATIVE NEOPLASMS RESEAR 180 N MICHIGAN AVENUE SUITE 1870 CHICAGO IL 60601 364330967 3 200000 ACCRUAL RESEARCH GRANT NEW YORK UNIVERSITY SCHOOL OF MEDIC SPONSORED PROGRAMS PO BOX 415026 BOSTON MA 022414150 135562308 3 135515 ACCRUAL RESEARCH GRANT NORTHWESTERN UNIVERSITY ACCOUNTING SERVICES FOR RESEARCH 633 CLARK - ROOM G547 EVANSTON IL 60208 362167817 3 135500 ACCRUAL RESEARCH GRANT OSU FOUNDATION 1960 KENNY ROAD 4TH FLOOR COLUMBUS OH 432101016 316025986 3 600000 ACCRUAL RESEARCH GRANT PERELMAN SCHOOL OF MEDICINE AT THE OFFICE OF RESEARCH SERVICES 3451 WALNUT STREET FRANKLIN BLDG P- PHILADELPHIA PA 191046205 231352685 3 869057 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIG BOX 223131 PITTSBURGH PA 152512131 386006309 3 660000 ACCRUAL RESEARCH GRANT ROCKEFELLER UNIVERSITY 1230 YORK AVENUE BOX 82 NEW YORK NY 10021 131624158 3 10000 ACCRUAL RESEARCH GRANT SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 911156519 3 74859 ACCRUAL RESEARCH GRANT SLOAN KETTERING INSTITUTE FOR CANCE SLOAN KETTERING INSTITUTE FOR CANCE MSKC FINANCE GENERAL POST OFFICE PO NEW YORK NY 10087 131924236 3 1727771 ACCRUAL RESEARCH GRANT ST JUDE CHILDREN'S RESEARCH HOSPIT PO BOX 1000 DEPT 949 MEMPHIS TN 381480949 620646012 3 300500 ACCRUAL RESEARCH GRANT TEMPLE UNIVERSITY RESEARCH ACCOUNTING SERVICES PO BOX 824242 PHILADELPHIA PA 191824242 231365971 3 200000 ACCRUAL RESEARCH GRANT THE CHILDREN'S HOSPITAL OF PHILADEL LOCKBOX 1457 PO BOX 8500 PHILADELPHIA PA 191781457 231352166 3 246150 ACCRUAL RESEARCH GRANT THE JACKSON LABORATORY 600 MAIN STREET BAR HARBOR ME 046091523 010211513 3 30000 ACCRUAL RESEARCH GRANT THE JOHNS HOPKINS UNIVERSITY SCHOOL JOHNS HOPKINS UNIVERSITY CENTRAL LO 12529 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 520595110 3 660000 ACCRUAL RESEARCH GRANT THE OHIO STATE UNIVERSITY 1960 KENNY ROAD 4TH FLOOR ATTN RICHARD BRADBURY COLUMBUS OH 432101016 316025986 3 579440 ACCRUAL RESEARCH GRANT THE REGENTS OF THE UNIVERSITY OF CA 9500 GILMAN DRIVE MC 0009 LA JOLLA CA 920930009 956006144 3 620000 ACCRUAL RESEARCH GRANT THE REGENTS OF THE UNIVERSITY OF CA UCSF MAIN DEPOSITORY LOS ANGELES CA 900744872 946036493 3 250000 ACCRUAL RESEARCH GRANT THE TRUSTEES OF COLUMBIA UNIVERSITY SPONSORED PROJECTS FINANCE NEW YORK NY 100879789 135598093 3 914500 ACCRUAL RESEARCH GRANT THE TRUSTEES OF THE UNIVERSITY OF P OFFICE OF RESEARCH SERVICES 3451 WALNUT STREET FRANKLIN BLDG P PHILADELPHIA PA 191046205 231352685 3 1609600 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF ALABAMA AT BIRMIN 1530 3RD AVENUE SOUTH SUITE 1170 BIRMINGHAM AL 352940111 636005396 3 500000 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF CHICAGO 5841 S MARYLAND AVE MC6092 CHICAGO IL 60637 362177139 3 436999 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF NORTH CAROLINA AT OFFICE OF SPONSORED RESEARCH IN CA PO BOX 402420 ATLANTA GA 303842420 566001393 3 303000 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF TEXAS MD ANDERSON ATTN GRANTS AND CONTRACTS PO BOX 4266 HOUSTON TX 772104266 746001118 3 1947088 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF TEXAS SOUTHWESTER PO BOX 841753 DALLAS TX 752841753 756002868 3 315500 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF UTAH 201 S PRESIDENTS CIRCLE RM 145 ACCOUNTS PAYABLE SALT LAKE CITY UT 841129003 876000525 3 5500 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA IRVINE OFFICE OF RESEARCH ADMINISTRATION 300 UNIVERSITY TOWER UNIVERSITY OF IRVINE CA 926977600 952540117 3 10000 ACCRUAL RESEARCH GRANT UNIVERSITY OF COLORADO DENVER ANSC ANSCHUTZ MEDICAL CAMPUS BLDG 500 PO BOX 6508 AURORA CO 80045 846000555 3 1301250 ACCRUAL RESEARCH GRANT UNIVERSITY OF COLORADO-DENVER 12700 E 19TH AVENUE AURORA CO 80045 846000555 3 50000 ACCRUAL RESEARCH GRANT UNIVERSITY OF FLORIDA 33 TIGERT HALL P O BOX 113001 GAINESVILLE FL 326113001 596002052 3 2060331 ACCRUAL RESEARCH GRANT UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION PO BOX 405803 ATLANTA GA 303845803 590624458 3 696891 ACCRUAL RESEARCH GRANT UNIVERSITY OF NOTRE DAME 511 MAIN BUILDING NOTRE DAME IN 46556 350868188 3 10000 ACCRUAL RESEARCH GRANT UNIVERSITY OF SOUTHERN CALIFORNIA SPONSORED PROJECTS ACCOUNTING FILE NO 52095 LOS ANGELES CA 90089 951642394 3 55000 ACCRUAL RESEARCH GRANT UNIVERSITY OF VIRGINIA ATTN OFFICE OF SPONSORED PROGRAMS PO BOX 400195 CHARLOTTESVILLE VA 229044195 237173411 3 115500 ACCRUAL RESEARCH GRANT VAN ANDEL RESEARCH INSTITUTE 333 BOSTWICK AVE NE GRAND RAPIDS MI 49503 522000820 3 120000 ACCRUAL RESEARCH GRANT VANDERBILT UNIVERSITY MEDICAL CENTE DEPT OF FINANCE ATTN STEVE TODD DEPT 1236 PO BOX 121236 DALLAS TX 75312 620476822 3 881576 ACCRUAL RESEARCH GRANT WASHINGTON UNIVERSITY IN ST LOUIS CAMPUS BOX 1034 700 ROSEDALE AVENUE ST LOUIS MO 63112 430653611 3 467000 ACCRUAL RESEARCH GRANT WASHINGTON UNIVERSITY SCHOOL OF MED SPONSORED PROJECTS ACCOUNTING 700 ROSEDALE AVENUE CAMPUS BOX 1034 ST LOUIS MO 631121408 430653611 3 829998 ACCRUAL RESEARCH GRANT WESTERN INSTITUTE FOR VETERANS RESE PO BOX 58719 SALT LAKE CITY UT 84158 870470748 3 431963 ACCRUAL RESEARCH GRANT YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS PO BOX 1873 NEW HAVEN CT 065201873 060646973 3 562500 ACCRUAL RESEARCH GRANT TULANE UNIVERSITY HEALTH SCIENCES C 1430 TULANE AVE EP15 NEW ORLEANS LA 70112 720423889 3 123385 ACCRUAL RESEARCH GRANT CITY OF HOPE NATIONAL MEDICAL CENTE 1500 EAST DUARTE ROAD DUARTE CA 910103000 951683875 3 400000 ACCRUAL RESEARCH GRANT RUTGERS UNIVERSITY 3 RUTGERS PLAZA NEW BRUNSWICK NJ 08901 226001086 3 120000 ACCRUAL RESEARCH GRANT OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD MAIL CODE L106 PORTLAND OR 97239 237083114 3 120000 ACCRUAL RESEARCH GRANT INSTITUTE FOR CANCER RESEARCH DBA 333 COTTMAN AVENUE PHILADELPHIA PA 191112434 232003072 3 120000 ACCRUAL RESEARCH GRANT RHODE ISLAND HOSPITAL 593 EDDY STREET ALDRICH 3-317 PROVIDENCE RI 02903 050258954 3 125000 ACCRUAL RESEARCH GRANT MEDICAL COLLEGE OF WISCONSIN 8701 W WATERTOWN PLANK RD MILWAUKEE WI 53226 390806261 3 125000 ACCRUAL RESEARCH GRANT DUKE UNIVERSITY DUKE UNIVERSITY ACCOUNTS RECEIVABLE PO BOX 602651 CHARLOTTE NC 282602651 560532129 3 124954 ACCRUAL RESEARCH GRANT MAYO CLINIC ARIZONA MAYO CLINIC RESEARCH PO BOX 860334 MINNEAPOLIS MN 554860334 860800150 3 200000 ACCRUAL RESEARCH GRANT CASE WESTERN RESERVE UNIVERSITY OFFICE OF RESEARCH ADMINISTRATION 10900 EUCLID AVENUE-NORD HALL SUITE CLEVELAND OH 441067037 341018992 3 125000 ACCRUAL RESEARCH GRANT PRESIDENT & FELLOWS OF HARVARD COLL PO BOX 415649 BOSTON MA 02241 042103580 3 499615 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MINNES NW5957 PO BOX 1450 MINNEAPOLIS MN 554855957 416007513 3 250000 ACCRUAL RESEARCH GRANT ABINTUS BIO 10355 SCIENCE CENTER DR 250 SAN DIEGO CA 92121 844349617 250000 FMV THERAPY ACCELERATION IMMUNE -ONC THERAPEUTICS INC 2431 ALOMA AVE 124 WINTER PARK FL 32792 593226705 1500000 FMV THERAPY ACCELERATION IMMUNITAS 830 WINTER ST WALTHAM MA 02451 842813217 500000 FMV THERAPY ACCELERATION 71 3 COPAY ASSISTANCE CLL 7168 49165474 COPAY ASSISTANCE LYMPHOMA 3768 11818318 COPAY ASSISTANCE MDS 3012 15863866 COPAY ASSISTANCE MYELOMA 15583 117657639 COPAY ASSISTANCE MANTEL 1704 11647828 COPAY ASSISTANCE WALDENST 2178 13256872 COPAY ASSISTANCE ALL 85 425000 COPAY ASSISTANCE AML 3338 16657899 COPAY ASSISTANCE CML 13 26000 PATIENT TRAVEL ASSISTANC 11486 5595139 PATIENT AID 27168 8251869 SCHEDULE I, PAGE 1, PART I, LINE 2 FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. X X X X X false false false false false false false true false LOUIS J DEGENNARO PRESIDENT & CEO 708367 281807 21012 21688 29516 1062390 GWEN NICHOLS MD EVP CHIEF MED OFFICE 436575 147258 25962 14444 29346 653585 TROY DUNMIRE EVP CHIEF OPER OFFIC 447424 144589 1443 14516 10420 618392 GORDON MILLER JR EVP CHIEF FIN OFFICE 363635 117372 1771 22281 33666 538725 DALE NISSENBAUM EVP GEN COUNSEL 372606 119073 1798 5510 13816 512803 COKER POWELL SVP CHIEF DEVELOPMNT 334633 85000 20320 22271 43532 505756 TOM OSGOOD EVP CHIEF HR 327515 105621 4533 16050 15351 469070 VANESSA WHITE SVP CHIEF ADV OFF 357849 65000 1212 15422 24274 463757 LEE M GREENBERGER SVP CHIEF SCIEN OFFI 316120 55304 12808 26167 39916 450315 SCHEDULE J, PAGE 1, PART I, LINE 7 LLS AWARDS NON-FIXED PAYMENTS SUCH AS BONUSES ON A DISCRETIONARY BASIS TIED TO THE EMPLOYEE PERFORMANCE AND ORGANIZATION TARGETS. THE NAMES OF EMPLOYEES AND THE AMOUNTS THAT WERE PAID ARE FOUND ON SCHEDULE J, PAGE 2, PART II, COL (B) (II). IN FY 22, LLS PAID BONUSES RELATED TO BOTH FY20 AND FY21 RESULTS. X 181 1729949 FAIR MARKET VALUE X 8 37250 FAIR MARKET VALUE X PRINTED ITEMS 6 37254 FAIR MARKET VALUE X VARIOUS OTHER 19 68237 FAIR MARKET VALUE false true false SCHEDULE M, PAGE 2, PART II PART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. FORM 990, PAGE 2, PART III, LINE 4A A) RESEARCH PROGRAMS: AT LLS, WE ARE PUSHING BOUNDARIES TOWARD POWERFUL NEW THERAPIES. WE PROPEL GROUNDBREAKING CANCER TREATMENTS THROUGH ALL PHASES OF THE DRUG APPROVAL PROCESS AND ARE PROUD THAT OUR SUPPORT HAS BEEN KEY TO ADVANCING 75% OF THE ALMOST 100 BLOOD CANCER TREATMENT APPROVALS OVER THE LAST FIVE YEARS. AS WE CONTINUED TO SUPPORT THE SEARCH FOR LIFESAVING AND LESS TOXIC TREATMENTS IN 2022, WE INVESTED IN EXCITING RESEARCH FRONTIERS, INCLUDING PRECISION MEDICINE, IMMUNOTHERAPY, AND LINKS BETWEEN MUTATIONS AND BLOOD CANCER-ADVANCEMENTS THAT ARE CHANGING THE PARADIGM OF CANCER TREATMENT. IN THE PROCESS, WE PROPELLED SEVERAL NOVEL SCIENCE INITIATIVES TO NEW HEIGHTS-MANY OF WHICH HARDLY SEEMED POSSIBLE JUST A SHORT TIME AGO. WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. TO DATE, LLS HAS INVESTED OVER 1.6 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. OUR SUSTAINED RESEARCH INVESTMENT OVER MULTIPLE DECADES HAS PAID OFF HANDSOMELY. THIS IS BEST DEMONSTRATED BY OUR SEMINAL INVESTMENT IN CHIMERIC ANTIGEN RECEPTOR T CELL (CAR T) THERAPY STARTING IN 1990 THAT, SINCE 2017, HAS TRANSLATED INTO A 12 FDA-APPROVED CAR T THERAPIES FOR ACUTE B-CELL LEUKEMIA, NON-HODGKIN LYMPHOMA, AND MULTIPLE MYELOMA. CAR T THERAPY HAS IN SOME CASES PRODUCED CURES IN PATIENTS WHO HAVE FAILED ALL OTHER THERAPEUTIC OPTIONS. IN FISCAL YEAR 2022, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 9 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 54.6 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. IMPACT RESEARCH GRANTS TO ADDRESS UNEQUAL REPRESENTATION OF UNDERSERVED POPULATIONS IN CLINICAL TRIALS, IN MAY WE INTRODUCED IMPACT (INFLUENTIAL MEDICINE PROVIDING ACCESS TO CLINICAL TRIALS) RESEARCH GRANTS. AN INITIAL FIVE-YEAR INVESTMENT OF 3.75 MILLION WAS ALLOCATED TO MAYO CLINIC, VANDERBILT UNIVERSITY MEDICAL CENTER, AND WEILL CORNELL MEDICINE IN NEW YORK CITY. WE NOW HAVE SIX IMPACT RESEARCH GRANTS IN PLACE SINCE OCTOBER 2022. THE IMPACT GRANTS WILL HELP THESE MAJOR CANCER CENTERS EXPAND CLINICAL TRIAL ACCESS TO LOCAL COMMUNITY-BASED HOSPITALS AND CLINICS WITH SUBSTANTIAL UNDERSERVED POPULATIONS. THE GOAL IS TO INCREASE TRIAL ENROLLMENT AMONG TRADITIONALLY UNDERSERVED POPULATIONS, INCLUDING RACIAL AND ETHNIC MINORITIES, RURAL RESIDENTS, AND INDIVIDUALS WITH LOW INCOME, TO AT LEAST 20%, THEREBY EXPANDING ACCESS TO STATE-OF-THE-ART THERAPIES TO A BROADER SWATH OF NEWLY DIAGNOSED BLOOD CANCER PATIENTS. THERAPY ACCELERATION PROGRAM (TAP) SINCE 2007, OUR INNOVATIVE VENTURE PHILANTHROPY INITIATIVE, THE LLS THERAPY ACCELERATION PROGRAM (TAP), HAS PARTNERED WITH OVER 70 BIOTECHNOLOGY COMPANIES AND ACADEMIC RESEARCHERS TO EXTEND THE THERAPEUTIC LANDSCAPE IN LEUKEMIA, LYMPHOMA, AND MULTIPLE MYELOMA BY INVESTING OVER 130 MILLION DOLLARS, AND SO FAR, LEADING TO 3 FDA APPROVALS. CURRENTLY, THERE ARE OVER 20 ACTIVE CLINICAL STUDIES WITH TAP-SUPPORTED THERAPIES, INCLUDING 4 LATE- STAGE CLINICAL STUDIES WITH CLINICAL DATA EXPECTED IN THE NEXT YEAR OR TWO THAT COULD LEAD TO NEW FDA APPROVALS FOR BLOOD CANCER PATIENTS. IN 2022, WE MADE FOUR INVESTMENTS IN COMPANIES DEVELOPING NEXT-GENERATION IMMUNOTHERAPIES INCLUDING TWO FROM EUROPE. THESE INVESTMENTS GO BEYOND THE TRADITIONAL T CELL THERAPY SUCH AS CAR-T OR BI-SPECIFICS AND INCLUDE TWO CHECKPOINT INHIBITORS USING MACROPHAGES OR MYELOID CELLS TO ELICIT THE ANTI-CANCER EFFECTS. WE ALSO INVESTED IN COMPANIES DEVELOPING NOVEL ANTIBODIES, ONE A GAMMA-DELTA T CELL ACTIVATING ANTIBODY FOR A VARIETY OF BLOOD CANCERS AND ANOTHER ANTIBODY FOR A NOVEL TARGET IN PATIENTS WITH RARE BLOOD CANCERS INCLUDING LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AND CYTOTOXIC LYMPHOMAS WHERE THERE IS NO STANDARD OF CARE AND CURRENT THERAPIES ARE TOO TOXIC FOR PATIENTS. ALL FOUR COMPANIES ARE IN ACTIVE CLINICAL DEVELOPMENT IN BLOOD CANCERS. NATIONAL PATIENT REGISTRY COVID INFORMATION THE ONGOING COVID-19 PANDEMIC ENGENDERED A HOST OF FEARS AND QUESTIONS FOR THE BLOOD CANCER COMMUNITY. WHEN PATIENT CONCERNS AROSE ABOUT WHETHER THE NEW VACCINES WOULD PROTECT THEM, LLS STEPPED IN TO FIND ANSWERS. IN FEBRUARY 2021, LLS ACTIVATED THE LLS NATIONAL PATIENT REGISTRY, A PROJECT SUPPORTED BY ETHEL AND BERNARD GARIL IN MEMORY OF THEIR SON, MICHAEL, WHO SUCCUMBED TO ACUTE LYMPHOBLASTIC LEUKEMIA. MORE THAN 10,000 BLOOD CANCER PATIENTS ANSWERED THE CALL TO JOIN THE REGISTRY AS "CITIZEN SCIENTISTS." THIS ALLOWED US TO GENERATE THE LARGEST DATA SET REPORTED TO DATE ON VACCINE SAFETY AND EFFICACY(INCLUDING BOOSTERS) ACROSS ALL MAJOR BLOOD CANCER AND TREATMENT TYPES. THIS INFORMATION HAS HELPED PATIENTS, HEALTHCARE PROVIDERS, AND PUBLIC HEALTH OFFICIALS MAKE MORE INFORMED CHOICES ABOUT COVID-19 PREVENTION. CLINICAL TRIALS BEAT AML MASTER TRIAL BEGINNING NOVEMBER 2016, LLS LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. PEDAL MASTER TRIAL IN 2022, LLS LAUNCHED LLS' PEDIATRIC ACUTE LEUKEMIA (PEDAL) MASTER CLINICAL TRIAL. THIS UNPRECEDENTED INTERNATIONAL COLLOBORATION BETWEEN LLS, THE NATIONAL CANCER INSTITUTE (NCI), THE CHILDREN'S ONCOLOGY GROUP (OCG) AND OTHER PARTNERS BREAKS NEW GROUND, BRINGING PRECISION MEDICINE TO THE TREATMENT OF PEDIATRIC RELAPSED ACUTE LEUKEMIA. RATHER THAN A "ONE SIZE FITS ALL" APPROACH, PEDAL USES GENOMICS AND OTHER BIOMARKERS TO CUSTOMIZE TREATMENT, ALLOWING INNOVATIVE THERAPIES TO BE MATCHED TO PATIENTS BASED ON THEIR UNIQUE TUMOR BIOLOGY. A WIDE RANGE OF TRIAL SCREENIN LOCATIONS - SPANNING EUROPE, AUSTRALIA, NEW ZEALAND, CANADA, AND OVER 200 US SITES - ENSURES WIDESPREAD PARTICIPATION. ARKANSAS CHILDRESN'S HOSPITAL BECAME THE FIRST US THERAPEUTIC TRIAL SITE IN 2022, WITH MORE TO COME. FORM 990, PAGE 2, PART III, LINE 4B B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1.5 MILLION PEOPLE ACROSS THE UNITED STATES (US) ARE CURRENTLY LIVING WITH OR ARE IN REMISSION FROM LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OF PATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. FINANCIAL ASSISTANCE OUR FINANCIAL ASSISTANCE PROGRAMS AIM TO LESSEN THE ECONOMIC TOLL ON PATIENTS AND FAMILIES TO HELP PATIENTS AFFORD LIFE-SAVING TREATMENTS. TO COUNTER CONTINUALLY RISING DRUG PRICES AND ALLEVIATE THE BURDENS FELT BY PATIENTS COPING WITH BLOOD CANCER, WE PROVIDED MORE THAN 75,400 PATIENTS WITH OVER 384M IN ASSISTANCE AWARDED, A 59% INCREASE OVER LAST YEAR. THE LION'S SHARE-OVER 371 MILLION- AWARDED TO SUPPORTED PATIENTS' INSURANCE PREMIUMS AND TREATMENT-RELATED CO-PAY AND CO-INSURANCE OUT OF POCKET COSTS THROUGH OUR CO-PAY ASSISTANCE PROGRAM. IN KEEPING WITH OUR COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION, LLS RECOGNIZES THAT NEED EXISTS THROUGHOUT ALL GEOGRAPHIC REGIONS AND WITHIN ALL PATIENT POPULATIONS, INCLUDING THOSE TRADITIONALLY UNDERREPRESENTED. IN FY22, FINANCIAL ASSISTANCE WAS PROVIDED TO PATIENTS WHO RESIDED IN 82% OF ALL U.S. COUNTIES AND 74% OF THE COUNTIES ACROSS THE U.S. WITH THE HIGHEST POVERTY RATES. CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2022, CO-PAY ASSISTANCE WAS PROVIDED TO OVER 36,800 PATIENTS. SUSAN LANG PRE CAR T-CELL THERAPY TRAVEL ASSISTANCE PROGRAM LLS PROVIDED OVER 420 GRANTS, EACH 2,500, FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS FOR PATIENTS WHO ARE BEING EVALUATED TO RECEIVE CAR T-CELL THERAPY AS EITHER STANDARD TREATMENT OR A CLINICAL TRIAL. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM LLS AWARDED A 500 GRANT TO OVER 11,050 PATIENTS FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS. URGENT NEED PROGRAM IN PARTNERSHIP WITH MOPPIE'S LOVE AND CHARLIE'S FUND, LLS PROVIDED A 500 GRANT TO NEARLY 11,750 PATIENTS AND FAMILIES IN ACUTE FINANCIAL NEED FOR NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES, AND FOOD. PATIENT AID PROGRAM LLS AWARDED ONE-TIME STIPENDS OF 100 TO OVER 15,400 PATIENTS TO HELP OFFSET NON-MEDICAL EXPENSES. SCHOLARSHIP FOR BLOOD CANCER SURVIVORS IN 2022, THE LLS SCHOLARSHIP FOR BLOOD CANCER SURVIVORS PROVIDED UP TO 7,500 IN TUITION SUPPORT TO 100 PATIENTS, FOR VIRTUAL OR IN-PERSON VOCATIONAL, TWO-YEAR, OR FOUR-YEAR UNDERGRADUATE EDUCATION. FORM 990, PAGE 2, PART III, LINE 4C C) PUBLIC HEALTH EDUCATION: LLS BELIEVES KNOWLEDGE IS POWER. AS ALWAYS, LLS HAS OFFERED THEIR INFORMATIONAL PROGRAMS IN VIRTUAL FORMATS, CONTINUING TO PROVIDE VITALLY NEEDED EDUCATION AND EMOTIONAL SUPPORT FOR THOSE IMPACTED BY BLOOD CANCER. ONGOING PANDEMIC CONCERNS TRAINED ONCOLOGY INFORMATION SPECIALISTS IN OUR INFORMATION RESOURCE CENTER (IRC) WERE AVAILABLE TO ANSWER PANDEMIC-RELATED AND OTHER QUESTIONS. NEARLY 26,000 INTERACTIONS BETWEEN THE IRC AND PATIENTS AND CAREGIVERS TOOK PLACE, WITH AVERAGE CALL LENGTHS UP 14% OVER 2021. FACILITATING CLINICAL TRIAL ACCESS THE LLS CLINICAL TRIAL SUPPORT CENTER (CTSC) GREW THROUGHOUT THE YEAR AS WE INCREASED OUR BI-LINGUAL AND PEDIATRIC EXPERTISE AMONG THE CTSC NURSE NAVIGATORS, AND CONTINUED TO EXPAND THE POSSIBILITY OF POSITIVE OUTCOMES FOR PATIENTS BY MATCHING THEM TO SUITABLE CLINICAL TRIALS. OUR NURSE NAVIGATORS ASSISTED 1,005 PATIENTS (ABOUT THE SAME AS IN 2021). OF THE 751 NEW PATIENTS ASSISTED, 19% ENTERED A TRIAL. OUTREACH TO UNDERSERVED GROUPS WE AUGMENTED EFFORTS TO EXPAND ACCESS TO LLS SERVICES AND RESOURCES BY BOLSTERING RELATIONS WITH COMMUNITY GROUPS AND LEADERS, NOTABLY IN THE BLACK AND LATINO COMMUNITIES, AND INCREASED OUR NUMBER OF BILINGUAL VOLUNTEERS. WE ALSO INCREASED ACCESSIBILITY OF OUR EDUCATION PROGRAMS TO RURAL PATIENTS AND FAMILIES VIA OUR VIRTUAL OFFERINGS. MOREOVER, WE EXPANDED PARTNERSHIPS WITH AFFINITY GROUPS INCLUDING: THE NATIONAL COALITION OF 100 BLACK WOMEN, THE BLACK CAUCUS OF THE AMERICAN LIBRARY, VISIONS Y COMPROMISO AND THE MEXICAN CONSULATE'S VENTANILLA DE SALUD PROGRAM. THE LLS MYELOMA LINK PROGRAM, LAUNCHED IN 2017, CONTINUED TO GAIN TRACTION. WE IMPROVED UNDERSTANDING OF TREATMENT OPTIONS BY PROVIDING IMPORTANT INFORMATION TO AFRICAN AMERICANS, WHO ARE TWICE AS LIKELY TO BE DIAGNOSED WITH MULTIPLE MYELOMA AS CAUCASIAN AMERICANS. IN 2022, LLS REACHED NEARLY 22,000 PEOPLE THROUGH MORE THAN 60 MYELOMA LINK EDUCATION AND OUTREACH ACTIVITIES IN 13 CITIES. EDUCATION AND PATIENT CONNECTIONS OUR VIRTUAL EDUCATION PROGRAMS PROVIDED BOTH PATIENTS AND FAMILIES, AS WELL AS HEALTH CARE PROFESSIONALS, ACCESS TO CONTENT INCLUDING BLOOD CANCER CONFERENCES, LOCAL EDUCATION PROGRAMS, NATIONAL WEBINARS, VIDEOS, LECTURES, AND PODCASTS. LLS'S HIGHLY VIEWED WEBSITE CONTINUES TO PROVIDE THE MOST UP TO DATE BLOOD CANCER INFORMATION INCLUDING ACCESS TO BLOGS, BOOKLETS, WORKBOOKS, FACT SHEETS AND MORE. IN ADDITION, 1,060 CANCER PATIENTS WERE PROVIDED WITH PERSONALIZED NUTRITION CONSULTATIONS BY LLS'S REGISTERED DIETITIAN. OUR PATIENT & COMMUNITY OUTREACH TEAM CONTINUED TO BRING PATIENTS TOGETHER VIA ONLINE LOCAL SUPPORT GROUPS AND CHATS. THE PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM MATCHED NEARLY 2,100 PATIENTS (UP 17% FROM 2021) WITH TRAINED VOLUNTEERS FACING THE SAME DISEASE, HELPING TO AVERT PANDEMIC-RELATED ISOLATION. IN ADDITION, MEMBERSHIP IN LLS COMMUNITY-OUR ONLINE SOCIAL NETWORK- WAS 19,181, AN INCREASED 8% OVER 2021. FORM 990, PAGE 2, PART III, LINE 4D D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2022: -LLS PROVIDED 14 CME/CE-GRANTING VIRTUAL EDUCATIONAL PROGRAMS, WITH 873 HEALTHCARE PROFESSIONALS IN ATTENDANCE. - OVER 28,000 PATIENTS AND PROFESSIONALS PARTICIPATED IN LIVE EDUCATION PROGRAMS DELIVERED VIRTUALLY AS WELL AS DELIVERED IN PERSON, LOCALLY AND REGIONALLY. --THERE WERE 104,173 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 35,663 VIRTUAL LECTURE VIEWS AND 97,685 PODCAST DOWNLOADS. FORM 990, PART V, LINE 4B CANADA FORM 990, PAGE 6, PART VI, LINE 4 IN JULY 2022, THE LLS BOARD APPROVED TWO NEW COMMITTEES - THE TALENT & COMPENSATION COMMITTEE AND THE THERAPY ACCELERATION PROGRAM COMMITTEE. FORM 990, PAGE 6, PART VI, LINE 11B THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CFO, SENIOR VICE PRESIDENT OF FINANCE, VICE PRESIDENT, CONTROLLER, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990, AS WILL BE FILED WITH THE IRS, WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS. FORM 990, PAGE 6, PART VI, LINE 12C ALL EMPLOYEES, VOLUNTEERS, CONSULTANTS, TEMPORARY EMPLOYEES, LOCAL BOARD MEMBERS, AND MEMBERS OF THE NATIONAL BOARD OF DIRECTORS ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL CONFLICT OF INTEREST DISCLOSURE FORMS ARE REVIEWED BY THE LEGAL DEPARTMENT AND, IF DEEMED NECESSARY, ESCALATED TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS FOR FURTHER REVIEW, EVALUATION, AND/OR MANAGEMENT OF ANY ACTUAL OR APPARENT CONFLICTS OF INTEREST. FORM 990, PAGE 6, PART VI, LINE 15A THE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS, MONITORS, AND APPROVES THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. THEIR DECISION IS INCLUDED IN THE APPROPRIATE MINUTES OF THE MEETING IN WHICH APPROVAL WAS GIVEN. IN JUNE 2022, THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET, APPROVED AND DOCUMENTED THE PROCESS IN THE COMMITTEE MINUTES. FORM 990, PAGE 6, PART VI, LINE 15B IN 2020, THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS OF OTHER OFFICERS AND KEY EMPLOYEES AND TO APPROVE THE PRESIDENT AND CEO'S RECOMMENDATIONS ON THEIR COMPENSATION LEVELS. FORM 990, PAGE 6, PART VI, LINE 17 ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA FORM 990, PAGE 6, PART VI, LINE 19 THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE UPON REQUEST FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990. BEAT AML LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY 8348268 -439113 LLS LLS PEDAL INITIATIVE LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY 3249974 -5676466 LLS LLS TAP MIRAGEN LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS LLS TAP X4 LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY 289500 LLS LLS TAP LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY -31819717 266676 LLS LLS TAP CONSTELLATION LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS LLS TAP KDAC LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS STOP MDS LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS THE LLS RESEARCH PROGRAMS INC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 133470494 PART VII DE 501C3 12A LLS INC true THE LLS RESEARCH FOUNDATION 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 133709252 PART VII DE 501C3 12A LLS INC true THE LLS OF CANADA 804 2 LANSING SQUARE TORONTO CA M2J4P8 PART VII CA NA false false false false false false false false false false false false false false false false false true false false SCHEDULE R THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC. IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC.